Clinical Trial Update: A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating three doses of G17DT for metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• G17DT

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED